Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Seripa

Showing results (41-50 of 225) with videos related to

Pageof 23
Sort By:
Cerebrovascular Diseases (Basel, Switzerland)|April 11, 2003
Relevance of interleukin-1 receptor antagonist intron-2 polymorphism in ischemic strokeDavide Seripa, Aldo Dobrina, Maurizio Margaglione, et al.
Aging Clinical and Experimental Research|March 6, 2017
Emerging biomarkers and screening for cognitive frailtyQingwei Ruan, Grazia D'Onofrio, Daniele Sancarlo, et al.
Journal of Alzheimer'S Disease : JAD|March 18, 2017
Information and Communication Technologies for the Activities of Daily Living in Older Patients with Dementia: A Systematic ReviewGrazia D'Onofrio, Daniele Sancarlo, Francesco Ricciardi, et al.
Immunotherapy|February 1, 2019
Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?Francesco Panza, Madia Lozupone, Vittorio Dibello, et al.
Frontiers in Aging Neuroscience|June 25, 2015
Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanismsFrancesco Panza, Vincenzo Solfrizzi, Davide Seripa, et al.
Biochemical and Biophysical Research Communications|March 28, 2008
Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma modelMonica Rinaldi, Daniela Fioretti, Sandra Iurescia, et al.
Journal of Alzheimer'S Disease : JAD|April 28, 2010
Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome?Vincenza Frisardi, Vincenzo Solfrizzi, Cristiano Capurso, et al.
Expert Review of Clinical Immunology|February 1, 2012
Solanezumab for the treatment of mild-to-moderate Alzheimer's diseaseBruno P Imbimbo, Simone Ottonello, Vincenza Frisardi, et al.
Expert Opinion on Investigational Drugs|January 13, 2011
Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?Bruno P Imbimbo, Francesco Panza, Vincenza Frisardi, et al.
Immunotherapy|November 25, 2010
Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's diseaseFrancesco Panza, Vincenza Frisardi, Bruno P Imbimbo, et al.
Pageof 23

Showing results (41-50 of 225) with videos related to

Sort By:
Pageof 23
Cerebrovascular Diseases (Basel, Switzerland)|April 11, 2003
Relevance of interleukin-1 receptor antagonist intron-2 polymorphism in ischemic strokeDavide Seripa, Aldo Dobrina, Maurizio Margaglione, et al.
Aging Clinical and Experimental Research|March 6, 2017
Emerging biomarkers and screening for cognitive frailtyQingwei Ruan, Grazia D'Onofrio, Daniele Sancarlo, et al.
Journal of Alzheimer'S Disease : JAD|March 18, 2017
Information and Communication Technologies for the Activities of Daily Living in Older Patients with Dementia: A Systematic ReviewGrazia D'Onofrio, Daniele Sancarlo, Francesco Ricciardi, et al.
Immunotherapy|February 1, 2019
Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?Francesco Panza, Madia Lozupone, Vittorio Dibello, et al.
Frontiers in Aging Neuroscience|June 25, 2015
Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanismsFrancesco Panza, Vincenzo Solfrizzi, Davide Seripa, et al.
Biochemical and Biophysical Research Communications|March 28, 2008
Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma modelMonica Rinaldi, Daniela Fioretti, Sandra Iurescia, et al.
Journal of Alzheimer'S Disease : JAD|April 28, 2010
Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome?Vincenza Frisardi, Vincenzo Solfrizzi, Cristiano Capurso, et al.
Expert Review of Clinical Immunology|February 1, 2012
Solanezumab for the treatment of mild-to-moderate Alzheimer's diseaseBruno P Imbimbo, Simone Ottonello, Vincenza Frisardi, et al.
Expert Opinion on Investigational Drugs|January 13, 2011
Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?Bruno P Imbimbo, Francesco Panza, Vincenza Frisardi, et al.
Immunotherapy|November 25, 2010
Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's diseaseFrancesco Panza, Vincenza Frisardi, Bruno P Imbimbo, et al.
Pageof 23